# Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer

> **NCT02342587** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 7 (actual)

## Conditions studied

- HER2-positive Refractory Advanced Cancer

## Interventions

- **DRUG:** Lapatinib

## Key facts

- **NCT ID:** NCT02342587
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-03
- **Primary completion:** 2016-01
- **Final completion:** 2016-08-21
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2017-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02342587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02342587, "Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02342587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*